Biocardia Inc (BCDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biocardia Inc (BCDA) has a cash flow conversion efficiency ratio of -0.643x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($2.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Biocardia Inc for the company's overall valuation and market capitalisation.
Biocardia Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Biocardia Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biocardia Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocardia Inc ranked by their cash flow conversion efficiency. Explore Biocardia Inc (BCDA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Securemetric Berhad
KLSE:0203
|
0.083x |
|
INFLECTION RESOURCES LTD.
F:5VJ
|
-0.009x |
|
Tower Resources Ltd
V:TWR
|
-0.017x |
|
Termorex
WAR:TRR
|
-0.028x |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
0.015x |
|
Beasley Broadcast Group Inc
NASDAQ:BBGI
|
0.064x |
|
Benalec Holdings Bhd
KLSE:5190
|
0.004x |
|
Intelligent Protection Management Corp
NASDAQ:IPM
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Biocardia Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Biocardia Inc from 1995 to 2025. View Biocardia Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $895.00K | $-7.44 Million | -8.308x | +13.36% |
| 2024-12-31 | $837.00K | $-8.03 Million | -9.589x | -254.11% |
| 2023-12-31 | $-1.60 Million | $-9.97 Million | 6.222x | +388.22% |
| 2022-12-31 | $4.89 Million | $-10.56 Million | -2.159x | -116.07% |
| 2021-12-31 | $10.38 Million | $-10.37 Million | -0.999x | -55.05% |
| 2020-12-31 | $19.18 Million | $-12.36 Million | -0.644x | +83.83% |
| 2019-12-31 | $2.37 Million | $-9.45 Million | -3.985x | -36.53% |
| 2018-12-31 | $3.79 Million | $-11.07 Million | -2.919x | -274.52% |
| 2017-12-31 | $11.12 Million | $-8.67 Million | -0.779x | -190.51% |
| 2016-12-31 | $20.58 Million | $-5.52 Million | -0.268x | -1223.91% |
| 2015-12-31 | $13.87 Million | $331.00K | 0.024x | +51.08% |
| 2014-12-31 | $13.54 Million | $214.00K | 0.016x | +678.90% |
| 2013-12-31 | $13.31 Million | $27.00K | 0.002x | +108.70% |
| 2012-12-31 | $13.29 Million | $-310.00K | -0.023x | +90.19% |
| 2011-12-31 | $12.98 Million | $-3.09 Million | -0.238x | +81.76% |
| 2010-12-31 | $3.28 Million | $-4.28 Million | -1.304x | -301.89% |
| 2009-12-31 | $14.74 Million | $-4.78 Million | -0.325x | -28.78% |
| 2008-12-31 | $10.70 Million | $-2.70 Million | -0.252x | +67.22% |
| 2007-12-31 | $61.28K | $-47.12K | -0.769x | +85.32% |
| 2006-12-31 | $141.55K | $-741.46K | -5.238x | -103.10% |
| 2005-12-31 | $176.73K | $-455.82K | -2.579x | -231.63% |
| 2004-12-31 | $963.58K | $-749.42K | -0.778x | -338.65% |
| 2003-12-31 | $1.68 Million | $-297.66K | -0.177x | +24.45% |
| 2002-12-31 | $2.09 Million | $-491.22K | -0.235x | +47.81% |
| 2001-12-31 | $3.40 Million | $-1.53 Million | -0.450x | -103.53% |
| 2000-12-31 | $6.27 Million | $-1.38 Million | -0.221x | +51.39% |
| 1999-12-31 | $2.20 Million | $-1.00 Million | -0.455x | -120.78% |
| 1998-12-31 | $3.40 Million | $-700.00K | -0.206x | -68.82% |
| 1997-12-31 | $4.10 Million | $-500.00K | -0.122x | 0.00% |
| 1996-12-31 | $4.10 Million | $-500.00K | -0.122x | +96.68% |
| 1995-12-31 | $-71.75K | $263.39K | -3.671x | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more